Study guide

4.2 Acute & Chronic Liver Disease

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

4.2 Acute & Chronic Liver Disease

Key Takeaways Explain This Topic AI

Hepatitis B serology: HBsAg indicates active infection, anti-HBs alone indicates vaccination immunity, anti-HBc IgM indicates acute infection, and HBeAg indicates high viral replication and infectivity.

Spontaneous Bacterial Peritonitis (SBP) is diagnosed by an ascitic fluid absolute neutrophil count ≥250 cells/mm³ (0.25 x 10⁹/L); management requires immediate IV 3rd generation cephalosporin plus IV human albumin (1.5 g/kg day 1, 1.0 g/kg day 3).

Child-Pugh score grades liver cirrhosis severity (Class A: 5-6, Class B: 7-9, Class C: 10-15) based on Bilirubin, Albumin, INR, Ascites, and Encephalopathy.

Primary Biliary Cholangitis (PBC) is marked by anti-mitochondrial antibody positivity (AMA-M2 >1:40 in 95%) and elevated ALP, treated with ursodeoxycholic acid (13-15 mg/kg/day).

Last updated: July 2026

  • Acute & Chronic Liver Disease
  • Viral & Metabolic Hepatitis

Liver disease presents across a continuum from acute injury to chronic inflammation, fibrosis, and end-stage cirrhosis.

Hepatitis B Serology Interpretation

Understanding Hepatitis B virus (HBV) serological markers is essential for evaluating clinical phase, infectivity, and vaccination status.

  • Clinical Status HBsAg Anti-HBs Total Anti-HBc Anti-HBc IgM HBeAg Anti-HBe HBV DNA
  • Acute Infection Positive Negative Positive Positive Positive Negative Very High (>10⁵ IU/mL)
  • Chronic Immune Active Positive Negative Positive Negative Positive Negative High (>2,000 IU/mL)

Chronic Inactive Carrier Positive Negative Positive Negative Negative Positive Low / Undetectable (<2,000 IU/mL)

  • Past Resolved Infection Negative Positive Positive Negative Negative Positive Undetectable
  • Vaccinated Immunity Negative Positive Negative Negative Negative Negative Undetectable
  • Occult HBV Infection Negative Negative Positive Negative Negative Positive/Negative Low (<200 IU/mL)

Treatment Indications : Antiviral therapy (Tenofovir disoproxil fumarate, Tenofovir alafenamide, or Entecavir) is indicated for HBV DNA >2,000 IU/mL, elevated ALT, and evidence of moderate-to-severe necroinflammation or liver fibrosis (F2 or greater).

Hepatitis C Virus (HCV)

Diagnosis : Initial screening with anti-HCV antibody. Active infection confirmed by quantitative HCV RNA PCR.

Direct-Acting Antivirals (DAAs) : All-oral, pangenotypic DAA combinations (e.g., Sofosbuvir/Velpatasvir for 12 weeks or Glecaprevir/Pibrentasvir for 8 weeks) achieve Sustained Virologic Response at 12 weeks (SVR12) in >95% of patients.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Formerly termed NAFLD, MASLD is defined by hepatic steatosis accompanied by at least one cardiometabolic risk factor (BMI ≥25 kg/m², type 2 diabetes, hypertension, or dyslipidemia) in the absence of significant alcohol consumption (≥30 g/day for men, ≥20 g/day for women).

Risk Stratification : Non-invasive fibrosis scoring systems are critical to identify MASH (steatohepatitis) with advanced fibrosis:

FIB-4 Index : Uses Age, AST, ALT, and Platelet count.

Low Risk (<1.30) : High negative predictive value (>90%) for advanced fibrosis; manage in primary care.

High Risk (>2.67) : High risk of advanced fibrosis (F3-F4); refer to hepatology.

Transient Elastography (FibroScan) : Liver stiffness measurement (LSM) <8 kPa rules out advanced fibrosis; LSM ≥12–15 kPa indicates cirrhosis.

Autoimmune & Inherited Liver Diseases

Diagnostic differentiation of non-viral chronic liver diseases relies on autoantibody panels, biochemical profiles, and genetic testing.

Disease Demographics / Features Key Diagnostic Markers Histology / Imaging First-Line Therapy

Primary Biliary Cholangitis (PBC) Women 40–60 yrs; fatigue, pruritus, hypercholesterolemia Anti-Mitochondrial Antibodies ( AMA-M2 positive in >95%); Elevated ALP & IgM Destruction of interlobular bile ducts (florid duct lesions) Ursodeoxycholic Acid (UDCA) 13–15 mg/kg/day; Obeticholic acid second-line

Primary Sclerosing Cholangitis (PSC) Men 20–40 yrs; strong association with IBD (75% UC) pANCA positive (~60%); Elevated ALP; AMA negative MRCP: Multifocal strictures and segment dilatations ("beaded" bile ducts) Endoscopic balloon dilation for dominant strictures; Liver transplantation

Autoimmune Hepatitis (AIH) Females > Males; acute or chronic hepatitis presentation Type 1 : ANA, SMA (anti-smooth muscle) positive; Type 2 : Anti-LKM1 positive; High IgG Interface hepatitis, plasma cell infiltrate, rosette formation High-dose oral Prednisolone + Azathioprine maintenance

Hereditary Hemochromatosis Autosomal recessive ( HFE C282Y homozygosity) Transferrin Saturation >45% ; Serum Ferritin >1000 µg/L Hepatic iron concentration (Prussian blue stain) Venesection (target ferritin 50–100 µg/L)

Wilson's Disease Age 5–35 yrs; liver failure, neuropsychiatric features Low serum ceruloplasmin (<0.2 g/L); 24-hr urinary copper >1 µmol/day Kayser-Fleischer rings (copper in Descemet's membrane) Copper chelators ( Penicillamine or Trientine); Zinc acetate

Alpha-1 Antitrypsin Deficiency Early-onset emphysema, hepatitis, cirrhosis Low serum α1-antitrypsin level; SERPINA1 PiZZ genotype PAS-positive, diastase-resistant globule inclusions in hepatocytes Supportive care; Avoid smoking; Liver transplantation

Cirrhosis & Portal Hypertension

Cirrhosis represents end-stage liver fibrosis characterized by regenerative nodule formation surrounded by fibrous bands.

  • Scoring Tools in Cirrhosis
  • Child-Pugh Classification

Assesses severity and 1-year survival in cirrhosis based on 5 variables (Bilirubin, Albumin, INR, Ascites, Encephalopathy):

Class A (5–6 points) : Well-compensated (1-year survival 100%).

Class B (7–9 points) : Significant functional compromise (1-year survival 80%).

Class C (10–15 points) : Decompensated cirrhosis (1-year survival 45%).

Model for End-Stage Liver Disease (MELD)

Predicts 3-month mortality in end-stage liver disease and is used to prioritize liver transplantation allocation. Calculated using: Serum Bilirubin, Serum Creatinine, INR, and Serum Sodium (MELD-Na) .

  • Complications of Decompensated Cirrhosis
  • 1. Ascites & Spontaneous Bacterial Peritonitis (SBP)

Paracentesis Evaluation : Diagnostic tap is mandatory for all new-onset ascites or hospital admissions with cirrhosis.

Serum-Ascites Albumin Gradient (SAAG) = Serum Albumin − Ascitic Fluid Albumin.

SAAG ≥11 g/L (High Gradient) : Indicates Portal Hypertension (cirrhosis, heart failure, Budd-Chiari).

SAAG <11 g/L (Low Gradient) : Non-portal cause (peritoneal carcinomatosis, tuberculous peritonitis, nephrotic syndrome).

Spontaneous Bacterial Peritonitis (SBP) : Infection of ascitic fluid without an intra-abdominal surgically treatable source.

Diagnostic Benchmark : Ascitic fluid absolute polymorphonuclear (PMN) neutrophil count ≥250 cells/mm³ (0.25 × 10⁹/L).

Immediate Protocol : Empiric IV Cefotaxime 2 g TDS (or Ceftriaxone 2 g OD) PLUS IV Human Albumin (1.5 g/kg body weight within 6 hours of admission, followed by 1.0 g/kg on day 3). Albumin reduces renal impairment from 30% to 10% and significantly improves survival.

Secondary Prophylaxis : Oral Ciprofloxacin 500 mg OD or Norfloxacin 400 mg OD long-term.

2. Hepatic Encephalopathy (HE)

HE results from neurotoxic substances (primarily ammonia) crossing the blood-brain barrier due to portosystemic shunting and impaired hepatic clearance.

West Haven Criteria :

Grade 1 : Mild confusion, altered mood, asterixis (flapping tremor) present.

Grade 2 : Lethargy, disorientation to time, inappropriate behavior.

Grade 3 : Somnolence, stupor, disorientation to place.

Grade 4 : Coma.

Precipitating Factors : Constipation, GI bleeding, infection (SBP, UTI), hypokalemic alkalosis, dehydration, sedatives.

Management : Identify and treat precipitants. First-line therapy is oral Lactulose (titrated to achieve 2–3 soft bowel movements daily; metabolizes to lactic acid, trapping NH₄⁺ in bowel). Second-line add-on is Rifaximin 550 mg BD (non-absorbable antibiotic reducing urease-producing gut flora).

3. Hepatorenal Syndrome (HRS-AKI)

HRS-AKI is functional renal failure caused by severe renal vasoconstriction secondary to splanchnic arterial vasodilation in portal hypertension.

Diagnostic Criteria :

Diagnosis of cirrhosis with ascites.

Acute Kidney Injury (AKI) per KDIGO criteria (increase in serum creatinine ≥26.5 µmol/L within 48 hours or ≥50% increase from baseline).

No response after at least 48 hours of withdrawal of diuretics and volume expansion with IV albumin (1 g/kg/day).

Absence of shock, structural kidney disease (proteinuria <0.5 g/day, microhematuria <50 RBCs/hpf), and nephrotoxic drug exposure.

Treatment : First-line medical therapy is IV Terlipressin (0.5–2 mg IV every 4–6 hours or continuous IV infusion 2–12 mg/day) combined with IV Human Albumin (20–40 g/day). Transjugular Intrahepatic Portosystemic Shunt (TIPS) or liver transplantation is definitive.